Complement C4d Antikörper

Produktnummer ABIN3026358

Der Maus Monoklonal anti-Complement C4d Antikörper wird verwendet zum Nachweis von Complement C4d in Proben von Human. Er wurde validiert für ELISA und IHC (p).

Kurzübersicht für Complement C4d Antikörper (ABIN3026358)

Target: Complement C4d (C4d) (Complement Component C4d (C4d))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser Complement C4d Antikörper ist unkonjugiert

Applikation: ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Güteklasse: Carrier-free

Klon: C4D204

Produktdetails anti-Complement C4d Antikörper

Verwendungszweck: C4d Antibody / Complement 4d (azide and preservative free)

Produktmerkmale: This antibody is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound protein. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of antibodies to specific target molecules. Following activation and degradation of the C4 Molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product C4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. C4d has been shown to be a significant predictor of transplant kidney graft survival. C4d antibody, combined with antibody to C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment.

Aufreinigung: Protein G affinity chromatography

Immunogen: Recombinant human C4d protein was used as the immunogen for this C4d antibody.

Isotyp: IgG1, kappa

Anwendungsinformationen

Applikationshinweise: The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the C4d antibody to be titered up or down for optimal performance.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 1 mM EDTA, pH 7.5-8.5, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C

Informationen zur Lagerung: Store the C4d antibody at 2-8oC.

Details zu Complement C4d

Target: Complement C4d (C4d) (Complement Component C4d (C4d))

Andere Bezeichnung: C4d

Hintergrund: This antibody is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound protein. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of antibodies to specific target molecules. Following activation and degradation of the C4 Molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product C4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. C4d has been shown to be a significant predictor of transplant kidney graft survival. C4d antibody, combined with antibody to C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment.